

# ALEXANDER DISEASE (AxD)

## What is AxD?

AxD is **an ultra-rare, genetic, progressive and typically fatal neurological disorder.**<sup>1</sup>

AxD is a type of **leukodystrophy** – a group of rare genetic disorders characterized by abnormal white matter in the central nervous system (CNS), impairing how nerve signals are transmitted between the brain and body.<sup>2</sup>

The condition is estimated to occur in **approximately 1 per 1 to 3 million people worldwide**, accounting for roughly 2% to 12% of all leukodystrophy cases.<sup>2-6</sup>



AxD can **occur at any age with no racial, ethnic or regional predominance.**<sup>2,3</sup>



The median length of post-onset survival ranges from **14 to 25 years**, depending on age of onset and severity of disease, with later onset generally associated with longer survival.<sup>2,7,8\*</sup>



People diagnosed with AxD typically experience disease progression over several months to years, **but the course of disease can be variable and unpredictable.**<sup>2</sup>

\*These data are based upon small samples, and the disease course is seen as variable and unpredictable across all age groups.

## What causes AxD?

**AxD is primarily associated with pathogenic variants (genetic changes that cause disease) in the glial fibrillary acidic protein (GFAP) gene, that can lead to overproduction and toxic accumulation of GFAP.**<sup>2</sup>

GFAP is responsible for regulating the shape and interactions of astrocytes, cells that support numerous important functions within the CNS.<sup>2</sup>

The accumulation of GFAP impairs the function of astrocytes, leading to abnormal white matter, neuron dysfunction and degeneration within the CNS.<sup>2</sup>

Changes in GFAP typically happen randomly (*de novo*) and are not inherited from a parent.<sup>3</sup> However, with improved recognition, more familial cases are being identified.<sup>3</sup>

## What are the signs and symptoms?

Individuals may experience progressive motor and cognitive dysfunction, a loss of independence and the inability to control muscles for swallowing, airway protection and purposeful movements.<sup>9</sup>

Symptoms are **highly variable**, although some are more common depending on the age of onset.<sup>8</sup>

### Common symptoms in earlier age of onset (<4 years old) individuals:<sup>3,8,9</sup>



Delayed intellectual development or intellectual disabilities



Delayed physical development (delayed motor skills or loss of acquired motor skills)



Gastrointestinal issues including vomiting



Seizures



Enlarged head size (macrocephaly)



Difficulty gaining weight

### Common symptoms in later age of onset (>4 years old) individuals:<sup>9,10</sup>



Speech problems



Difficulty swallowing



Poor coordination, gait issues and loss of mobility



Scoliosis



Autonomic dysfunction including bladder abnormalities

## How is AxD diagnosed?

Doctors look for signs of AxD through a **combination of clinical presentation and brain magnetic resonance imaging (MRI) findings.**<sup>2</sup>



**A genetic test for pathogenic variants in the *GFAP* gene is usually needed to make the diagnosis.**<sup>2</sup>

Clinical diagnosis is challenging because **symptoms and MRI findings can vary** and mimic other more common neurological conditions (like multiple sclerosis), which can lead to **delayed diagnosis or misdiagnosis.**<sup>3</sup>

### Brain MRIs typically show:



Frontal white matter abnormalities in individuals with earlier age of onset.<sup>7,11,12</sup>



Lesions or shrinkage of the brainstem, cerebellum and/or cervical spinal cord in individuals with later age of onset.<sup>7,11,12</sup>

Given the **disease's progressive nature, prompt diagnosis is critical** to allow for earlier interventions that **may improve quality of life** through reduced symptom severity.<sup>2</sup>

## How is AxD evaluated and treated today?

While there are no standard validated assessments specific to AxD, the below measures can be useful for monitoring motor function at various disease stages:<sup>10</sup>

- ✓ **10-Meter Walk Test (10-MWT)** a clinician-administered test where walking speed is measured over 10 meters.<sup>13</sup>
- ✓ **Vineland Adaptive Behavior Scales (VABS)** a caregiver-reported questionnaire that measures an individual's everyday adaptive skills.<sup>14</sup>
- ✓ **Gross Motor Function Measure-88 (GMFM-88)** a clinician-scored assessment of gross motor abilities based on observed performance of standardized tasks.<sup>15</sup>

### Treatment approaches

Treatment for AxD may include symptom-directed supportive care to manage individual physical symptoms (e.g. seizures, dysphagia, and mobility difficulties) as well as psychiatric and cognitive challenges. It may also include treatments intended to target the underlying mechanism of AxD, with the goal of reducing overall disease severity rather than addressing specific symptoms.<sup>2,9</sup>

### For more information on AxD, visit the following resources

#### People living with AxD:

- **EndAxD.org** (the End Alexander Disease Foundation)
- **ULF.org** (the United Leukodystrophy Foundation)
- **Alexanderdisease.com/patient**

#### Healthcare Providers:

- **Alexanderdisease.com**

### References

- 1 Messing A. Alexander disease. *Handb Clin Neurol*. 2018;148:693-700.
- 2 Kuhn J, Cascella M. Alexander disease. In: *StatPearls*. Treasure Island (FL): StatPearls Publishing; September 4, 2023.
- 3 National Organization for Rare Disorders. Alexander disease. <https://rarediseases.org/rare-diseases/alexander-disease/>. Accessed August 25, 2025.
- 4 Yoshida T, Sasaki M, Yoshida M, et al. Nationwide survey of Alexander disease in Japan and proposed new guidelines for diagnosis. *J Neurol*. 2011;258(11):1998-2008.
- 5 Stellitano LA, Winstone AM, van der Knaap MS, Verity CM. Leukodystrophies and genetic leukoencephalopathies in childhood: a national epidemiological study. *Dev Med Child Neurol*. 2016;58(7):680-689.
- 6 Vanderver A, Hussey H, Schmidt JL, et al. Relative incidence of inherited white matter disorders in childhood to acquired pediatric demyelinating disorders. *Semin Pediatr Neurol*. 2012;19(4):219-223.
- 7 Pareyson D, Fancellu R, Mariotti C, et al. Adult-onset Alexander disease: a series of eleven unrelated cases with review of the literature. *Brain*. 2008;131(Pt 9):2321-2331.
- 8 Prust M, Wang J, Morizono H, et al. GFAP mutations, age at onset, and clinical subtypes in Alexander disease. *Neurology*. 2011;77(13):1287-1294.
- 9 Zampini L, Draghi L, Zanchi P. Developmental profiles in children and young adults with Alexander disease. *Dev Neurorehabil*. 2023;26(4):253-261.
- 10 Adang LA, Sherbini O, Ball L, et al. Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies. *Mol Genet Metab*. 2017;122(1-2):18-32.
- 11 Balbi P, Salvini S, Fundarò C, et al. The clinical spectrum of late-onset Alexander disease: a systematic literature review. *J Neurol*. 2010;257(12):1955-1962.
- 12 Farina L, Pareyson D, Minati L, et al. Can MR imaging diagnose adult-onset Alexander disease? *AJNR Am J Neuroradiol*. 2008;29(6):1190-1196.
- 13 Yaras A, Harrington A, Kornafel T, et al. Construct Validity of the 10-meter Walk/Run Test to Assess Motor Impairment in Patients with Alexander Disease. *Neurology*. 2024;102(7 Suppl 1).
- 14 Park G, Kim J, Lee T, Kim H-W. Clinical Significance of the Vineland Adaptive Behavior Scale-II in Children With Developmental Disabilities. *JAMA Netw Open*. 2024;7(6):e2417892.
- 15 Francesco G, Kornafel T, Pierce S, et al. Assessment of Gross Motor Function in Alexander Disease (AxD). *Neurology*. 2024;102(22 Suppl):P10-6.003. Presented at: American Academy of Neurology Annual Meeting; April 2024; Denver, CO.